![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
Cucurbit[7]uril: an emerging candidate for pharmaceutical excipients
Kit Ieng Kuok1, Shengke Li1, Ian W Wyman2
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau SAR, China.
Annals of the New York Academy of Sciences
|July 11, 2017
Summary
Cucurbit[7]uril (CB[7]) shows promise as a pharmaceutical excipient. It can form complexes with drugs, improving their properties like solubility and stability for better therapeutic outcomes.
Area of Science:
- Supramolecular Chemistry
- Pharmaceutical Sciences
- Materials Science
Background:
- Cucurbit[n]urils (CB[n]) are macrocyclic hosts capable of forming inclusion complexes with various molecules.
- Cucurbit[7]uril (CB[7]) is a prominent member of this family with potential biomedical applications.
Purpose of the Study:
- To review recent research (2011-2017) on CB[7]'s biocompatibility and its effects on drug properties.
- To highlight CB[7]'s potential as a pharmaceutical excipient for drug delivery.
Main Methods:
- Systematic literature review of studies investigating CB[7]-drug interactions.
- Analysis of data concerning CB[7]'s influence on drug stability, solubility, biouptake, and biological activity.
Main Results:
- CB[7] complexation generally enhances drug solubility, stability, and biouptake.
- The biocompatibility of CB[7] supports its use in pharmaceutical formulations.
- Modulation of therapeutic efficacy and toxicity of guest drugs by CB[7] was observed.
Conclusions:
- CB[7] demonstrates significant potential as a pharmaceutical excipient.
- Further research is encouraged to fully leverage CB[7] for improving drug properties and therapeutic outcomes.
More Related Videos
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
208
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
208
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
217
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
217
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
663
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
663
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
59
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
59
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
268
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
268
01:26Pharmaceutical Equivalents
230
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
230